PRCC also displays mutations in previously studied cancer-related pathways; these include NF2 (Hippo pathway), SMARCB1 and PBRM1 (SWI/SNF complex), and chromatin modifier pathways (SETD2, KDM6A, and BAP1). This evidence concerns the gene PRCC and cancer.